Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lucinactant for · 1 trial · 1 indication
Pre-specified adverse events that occured during treatment administration; does not include nCPAP alone
Oxygen saturation as determined by pulse oximetry
| Arm | Type | Description |
|---|---|---|
| Aerosolized lucinactant (25 mg/kg) | EXPERIMENTAL | 25 mg total phospholipids (TPL)/kg: Lucinactant for inhalation with nCPAP |
| Aerosolized lucinactant (50 mg/kg) | EXPERIMENTAL | 50 mg TPL/kg: Lucinactant for inhalation with nCPAP |
| Aerosolized lucinactant (75 mg/kg) | EXPERIMENTAL | 75 mg TPL/kg: Lucinactant for inhalation with nCPAP |
| Aerosolized lucinactant (100 mg/kg) | EXPERIMENTAL | 100 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met. |
| Aerosolized lucinactant (150 mg/kg) | EXPERIMENTAL | 150 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met. |
| nCPAP alone | ACTIVE_COMPARATOR | nCPAP therapy alone |
| Name | Type | Description |
|---|---|---|
| Lucinactant for Inhalation | DRUG | Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product) |
| nCPAP alone | DEVICE | nCPAP therapy |
Inclusion Criteria: * Informed consent from a legally authorized representative * Gestational age 29 to 34 completed weeks (34 weeks 6 days) post menstrual age (PMA) * Successful implementation of controlled nCPAP within 90 minutes after birth * Spontaneous breathing * Chest radiograph consistent w...
Lucinactant is an investigational drug being studied for Acute Hypoxemic Respiratory Failure, Respiratory Distress Syndrome, and COVID-19. It is developed by Windtree Therapeutics, Inc. (ticker: WINT). Lucinactant is currently in Phase 2 clinical development and is not yet approved by the FDA.
Lucinactant is a small molecule being developed by Windtree Therapeutics, Inc. (ticker: WINT). It is being studied for conditions such as Acute Hypoxemic Respiratory Failure, Respiratory Distress Syndrome, and COVID-19. Lucinactant is currently in Phase 2 clinical trials.
Lucinactant is being developed by Windtree Therapeutics, Inc., a biopharmaceutical company traded under the ticker WINT. The drug is currently in Phase 2 clinical development for Acute Hypoxemic Respiratory Failure, Respiratory Distress Syndrome, and COVID-19.
Lucinactant is in Phase 2 clinical development. It is being studied for Acute Hypoxemic Respiratory Failure, Respiratory Distress Syndrome, and COVID-19. Lucinactant is an investigational drug and has not been approved by the FDA. Windtree Therapeutics, Inc. (ticker: WINT) is the developer.
Lucinactant has completed three Phase 2 trials: NCT00578734 for Acute Hypoxemic Respiratory Failure in children, NCT02074059 for Respiratory Distress Syndrome in premature neonates, and NCT04389671 for COVID-19 and Acute Lung Injury/ARDS in adults. These trials were conducted by Windtree Therapeutics, Inc. (ticker: WINT).
Lucinactant is also known by the brand name Surfaxin. It is being developed by Windtree Therapeutics, Inc. (ticker: WINT) for Acute Hypoxemic Respiratory Failure, Respiratory Distress Syndrome, and COVID-19. Lucinactant is currently in Phase 2 clinical trials.